[go: up one dir, main page]

MX2022009736A - Compuestos y metodos de p2x3 y/o p2x2/3. - Google Patents

Compuestos y metodos de p2x3 y/o p2x2/3.

Info

Publication number
MX2022009736A
MX2022009736A MX2022009736A MX2022009736A MX2022009736A MX 2022009736 A MX2022009736 A MX 2022009736A MX 2022009736 A MX2022009736 A MX 2022009736A MX 2022009736 A MX2022009736 A MX 2022009736A MX 2022009736 A MX2022009736 A MX 2022009736A
Authority
MX
Mexico
Prior art keywords
compounds
sub
methods
useful
administering
Prior art date
Application number
MX2022009736A
Other languages
English (en)
Inventor
Ashis Saha
Scott K Thompson
Tony Priestley
Mrinalkanti Kundu
Suvadeep Nath
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of MX2022009736A publication Critical patent/MX2022009736A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos novedosos y métodos para preparar y utilizar estos compuestos. En una modalidad, los compuestos tienen la estructura de la fórmula (I), en donde R1-R7 se definen en el presente documento. En una modalidad adicional, estos compuestos son útiles en un método para regular uno o ambos de los receptores P2X3 o P2X2/3. En otra modalidad, estos compuestos son útiles para tratar el dolor en pacientes mediante la administración de uno o más de los compuestos a un paciente. En otra modalidad, estos compuestos son útiles para tratar la disfunción respiratoria en pacientes mediante la administración de uno o más de los compuestos a un paciente. (ver Fórmula).
MX2022009736A 2016-09-30 2019-03-28 Compuestos y metodos de p2x3 y/o p2x2/3. MX2022009736A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662402280P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
MX2022009736A true MX2022009736A (es) 2022-09-05

Family

ID=61757797

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003710A MX2019003710A (es) 2016-09-30 2017-09-27 Compuestos y metodos de p2x3 y/o p2x2/3.
MX2022009736A MX2022009736A (es) 2016-09-30 2019-03-28 Compuestos y metodos de p2x3 y/o p2x2/3.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019003710A MX2019003710A (es) 2016-09-30 2017-09-27 Compuestos y metodos de p2x3 y/o p2x2/3.

Country Status (13)

Country Link
US (5) US10174039B2 (es)
EP (1) EP3528813B1 (es)
KR (1) KR20190053963A (es)
CN (2) CN109996546B (es)
AR (1) AR109776A1 (es)
AU (1) AU2017335674A1 (es)
BR (1) BR112019006216A2 (es)
CA (1) CA3037748A1 (es)
IL (1) IL265648B2 (es)
MX (2) MX2019003710A (es)
RU (1) RU2019112740A (es)
TW (1) TW201827432A (es)
WO (1) WO2018064135A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019112740A (ru) * 2016-09-30 2020-11-02 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи P2x3 и/или p2x2/3 соединения и способы
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
JP7578602B2 (ja) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
CA3187566A1 (en) 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
EP4251273B1 (en) * 2020-11-27 2025-03-12 Chiesi Farmaceutici S.p.A. Phthalazine derivatives as p2x3 inhibitors
MX2023005805A (es) * 2020-11-27 2023-06-01 Chiesi Farm Spa Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
KR20240137134A (ko) 2021-12-21 2024-09-19 코어셉트 쎄라퓨틱스 인코포레이티드 피페라진 인다졸 글루코코르티코이드 수용체 길항제
JP2025501553A (ja) 2021-12-21 2025-01-22 コーセプト セラピューティクス， インコーポレイテッド 二環式インダゾールグルココルチコイド受容体拮抗薬
CN114685308A (zh) * 2022-05-10 2022-07-01 杭州微流汇科技有限公司 一种自催化氰源一锅法制备芳基伯酰胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5633002A (en) 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5411738A (en) 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
JP3471122B2 (ja) 1995-04-26 2003-11-25 アルケア株式会社 医療用粘着配合物
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
WO1998043555A1 (en) 1997-04-03 1998-10-08 Point Biomedical Corporation Intravesical drug delivery system
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
KR20030068136A (ko) 2000-10-13 2003-08-19 알자 코포레이션 미세 돌기부로 피부를 천공하기 위한 장치 및 방법
WO2002094368A1 (en) 2000-10-26 2002-11-28 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
ATE455545T1 (de) 2001-11-01 2010-02-15 Spectrum Pharmaceuticals Inc Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
EP1348707B1 (en) 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
AU2003240493B2 (en) 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
CA2587780A1 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
US20070039624A1 (en) * 2005-08-18 2007-02-22 Roberts Richard H Patient compliance system and method to promote patient compliance
JP2007055940A (ja) 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
WO2007063935A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
CN101528717B (zh) * 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
WO2010054296A2 (en) 2008-11-07 2010-05-14 Combinent Biomedical Systems, Inc. Devices and methods for treating and/or preventing diseases
US20110046600A1 (en) 2008-12-05 2011-02-24 Crank Justin M Devices, systems, and related methods for delivery of fluid to tissue
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2011063076A1 (en) * 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
CN103492389B (zh) * 2011-04-21 2016-09-14 原真股份有限公司 用作激酶抑制剂的吡唑并[4,3-d]嘧啶
CN105246888B (zh) * 2013-01-31 2017-09-05 尼奥迈德研究所 咪唑并吡啶化合物及其用途
KR20220112867A (ko) 2013-12-16 2022-08-11 에이비에스 디벨롭먼트 원 인코포레이티드 P2x3 및/또는 p2x2/3 화합물 및 방법
CZ307147B6 (cs) * 2015-05-14 2018-02-07 Ústav experimentální botaniky AV ČR, v. v. i. 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
RU2019112740A (ru) * 2016-09-30 2020-11-02 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи P2x3 и/или p2x2/3 соединения и способы

Also Published As

Publication number Publication date
TW201827432A (zh) 2018-08-01
EP3528813A1 (en) 2019-08-28
IL265648B2 (en) 2025-07-01
BR112019006216A2 (pt) 2019-06-25
EP3528813B1 (en) 2025-04-16
CN116854693A (zh) 2023-10-10
EP3528813A4 (en) 2020-06-03
US10611768B2 (en) 2020-04-07
US10174039B2 (en) 2019-01-08
CN109996546A (zh) 2019-07-09
US20200190096A1 (en) 2020-06-18
US20240391925A1 (en) 2024-11-28
AU2017335674A1 (en) 2019-04-18
CN109996546B (zh) 2023-06-27
CA3037748A1 (en) 2018-04-05
RU2019112740A (ru) 2020-11-02
IL265648A (en) 2019-05-30
US20190092778A1 (en) 2019-03-28
US20180093991A1 (en) 2018-04-05
US11339169B2 (en) 2022-05-24
AR109776A1 (es) 2019-01-23
US20220227774A1 (en) 2022-07-21
US12077543B2 (en) 2024-09-03
KR20190053963A (ko) 2019-05-20
MX2019003710A (es) 2019-06-24
IL265648B1 (en) 2025-03-01
WO2018064135A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX2022009736A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
CY1125963T1 (el) Ρυθμιστες υποδοχεα ρ2χ3 και ρ2χ2/3 διαμινοπυριμιδινης για χρηση στη θεραπεια βηχα
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1125247T1 (el) Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2
CO2019008932A2 (es) Imidazo-quinolinas sustituidas como moduladores de nlrp3
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201790693A1 (ru) Коррекция фигуры
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CY1124734T1 (el) Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX391156B (es) Forma polimorfica de sepiapterina.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
CO2017010151A2 (es) Material de implante compuesto
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
EA201792170A1 (ru) Производные индола